The France Foundation
We offer timely, relevant, and engaging continuing education that helps healthcare providers deliver the best medical care, and ultimately improve the lives of patients. Our accredited education accelerates the understanding of new evidence and facilitates the acquisition of new behaviors, because they are designed to increase retention, inspire action, and improve results at the point-of-care.
The France Foundation is accredited as a provider of interprofessional continuing education (IPCE) by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nursing Credentialing Center (ANCC).
Освоение КТВР: ключевая роль рентгенолога в лечении фиброзных ИЛЗ
Достижения в лечении ИТП у детей: что вам нужно знать
Bronchiectasis Decoded: Pathophysiology, Diagnosis, and Emerging Treatments
Центральная роль ревматолога в лечении SARD ILD
9446 ATTR-CM Case Challenges: Success Strategies for Genetic Testing
Methamphetamine-Associated Pulmonary Arterial Hypertension (METH-PAH)
Updates in FVllla Mimetics: Advancing Hemophilia Treatment Today and Tomorrow
Expanding DMD Treatment Horizons New Evidence
COPD and Asthma Discussion - Key Takeaways (Video 3)
COPD and Asthma Discussion - Key Takeaways (Video 2)
COPD and Asthma Discussion - Key Takeaways (Video 1)
Barriers to Biologic Therapy in Asthma and COPD
Biologic Medicines for COPD
Lung Immunology in Asthma and COPD
Advancements In Pediatric ITP: What You Need to Know
Future Horizons for Fibrosing ILDs A Focus on IPF and PFF
Management of Serious Adverse Events: Part 2 (Kidney/Renal and Hepatic/Liver)
DMD Gene Therapy Clinical Trial Updates: Part 1
Clinical Considerations for Selecting DMD Therapy: Part 2
Clinical Considerations for Selecting DMD Therapy: Part 1
The Immunology of Obstructive Lung Disease and the Emergence of Biologics
Understanding BTK Inhibitors: What Every Nurse Needs to Know
The Heart of the Matter: Cardiovascular Risks With BTK Inhibitors
Assessing and Managing Cardiovascular Risk in Patients With CLL
Expert Interaction #1: Gene Therapy Clinical Trial Updates 1 (Delandistrogene and GNT0004)
Updates in Exon Skipping
Clinical Considerations for Selecting DMD Therapy: Part 1
Clinical Considerations for Selecting DMD Therapy: Part 2
Combination Therapy Strategies
Caregiver Global Impressions of Gene Therapy